Endo International PLC (NASDAQ:ENDP) (TSE:ENL) had its price target lowered by Cantor Fitzgerald from $9.00 to $7.00 in a research report report published on Friday. The firm currently has a neutral rating on the stock.
Several other equities research analysts have also recently weighed in on the company. Oppenheimer Holdings, Inc. restated a hold rating on shares of Endo International PLC in a report on Sunday, July 23rd. ValuEngine cut Endo International PLC from a buy rating to a hold rating in a report on Friday, September 1st. Zacks Investment Research upgraded Endo International PLC from a hold rating to a buy rating and set a $9.75 target price for the company in a report on Wednesday, October 11th. Royal Bank Of Canada set a $9.00 target price on Endo International PLC and gave the company a hold rating in a report on Tuesday, October 17th. Finally, BidaskClub upgraded Endo International PLC from a sell rating to a hold rating in a report on Wednesday, July 19th. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and five have issued a buy rating to the company. Endo International PLC currently has a consensus rating of Hold and a consensus target price of $11.67.
Shares of Endo International PLC (NASDAQ ENDP) traded up $0.08 during mid-day trading on Friday, reaching $6.78. The company had a trading volume of 1,791,781 shares, compared to its average volume of 7,354,719. The stock has a market cap of $1,490.00, a PE ratio of 1.43 and a beta of 0.53. Endo International PLC has a 52 week low of $5.77 and a 52 week high of $18.63. The company has a debt-to-equity ratio of 10.78, a current ratio of 1.08 and a quick ratio of 0.86.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last issued its earnings results on Thursday, November 9th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.06. The company had revenue of $786.90 million during the quarter, compared to analysts’ expectations of $794.93 million. Endo International PLC had a positive return on equity of 66.98% and a negative net margin of 126.97%. Endo International PLC’s quarterly revenue was down 11.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.01 EPS. research analysts anticipate that Endo International PLC will post 3.54 EPS for the current fiscal year.
A number of hedge funds have recently bought and sold shares of ENDP. James Investment Research Inc. bought a new position in Endo International PLC during the 2nd quarter valued at approximately $113,000. Blair William & Co. IL bought a new position in Endo International PLC during the 2nd quarter valued at approximately $126,000. LMR Partners LLP bought a new position in Endo International PLC during the 3rd quarter valued at approximately $148,000. Point View Wealth Management Inc. increased its position in Endo International PLC by 16.6% during the 2nd quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock valued at $149,000 after buying an additional 1,900 shares in the last quarter. Finally, Riverhead Capital Management LLC increased its position in Endo International PLC by 64.4% during the 2nd quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock valued at $168,000 after buying an additional 5,887 shares in the last quarter. 90.50% of the stock is owned by institutional investors.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.